A multi-center phase III randomized controlled study to evaluate the efficacy of
Hypofractionated SRS (HFSRS) along with EGFR-TKI in patients with brain metastasis from
non-small cell lung cancer (NSCLC). Assuming that HFSRS is not inferior to EGFR-TKI
concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS
(iPFS), while secondary outcomes included overall survival (OS), evaluation of cognitive
function, quality of life (QoL) and adverse events.